Register Login
Register to leave comments
  • News bot June 30, 2026, 11:25 p.m.

    🔍 BENZENO SHARON (Executive)

    Company: Adaptive Biotechnologies Corp (ADPT)

    Report Date: 2026-06-26

    Transaction Summary:

    • Total transactions: 12
    • Derivative instruments: 5
    • Holdings reported: 0
    • Total shares acquired: 114,329
    • Total shares sold: 280,131

    Detailed Transactions and Holdings:

    • Acquired 11,034 shares of Common Stock at $12.14 per share (Direct)
      Date: 2026-06-26 | Code: M | equity_swap_involved: 0 | shares_owned_after: 283,785.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 11,034 shares of Common Stock at $21.0 per share (Direct)
      Date: 2026-06-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 272,751.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Acquired 1,837 shares of Common Stock at $12.14 per share (Direct)
      Date: 2026-06-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 274,588.00 | transaction_form_type: 4 | Footnotes: F1
    • Acquired 24,944 shares of Common Stock at $8.46 per share (Direct)
      Date: 2026-06-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 299,532.00 | transaction_form_type: 4 | Footnotes: F1
    • Acquired 24,944 shares of Common Stock at $3.99 per share (Direct)
      Date: 2026-06-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 324,476.00 | transaction_form_type: 4 | Footnotes: F1
    • Acquired 51,570 shares of Common Stock at $8.12 per share (Direct)
      Date: 2026-06-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 376,046.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 154,768 shares of Common Stock at $21.14 per share (Direct)
      Date: 2026-06-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 221,278.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 11,034 shares of Stock Option (right to buy) at $12.14 per share (Derivative)
      Date: 2026-06-26 | Code: M | Expires: 2032-03-04 | equity_swap_involved: 0 | shares_owned_after: 1,837.00 | transaction_form_type: 4 | Footnotes: F1, F4
    • Sold 1,837 shares of Stock Option (right to buy) at $12.14 per share (Derivative)
      Date: 2026-06-29 | Code: M | Expires: 2032-03-04 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F4
    • Sold 24,944 shares of Stock Option (right to buy) at $8.46 per share (Derivative)
      Date: 2026-06-29 | Code: M | Expires: 2033-03-06 | equity_swap_involved: 0 | shares_owned_after: 37,416.00 | transaction_form_type: 4 | Footnotes: F1, F5
    • Sold 24,944 shares of Stock Option (right to buy) at $3.99 per share (Derivative)
      Date: 2026-06-29 | Code: M | Expires: 2034-03-04 | equity_swap_involved: 0 | shares_owned_after: 87,303.00 | transaction_form_type: 4 | Footnotes: F1, F6
    • Sold 51,570 shares of Stock Option (right to buy) at $8.12 per share (Derivative)
      Date: 2026-06-29 | Code: M | Expires: 2035-03-04 | equity_swap_involved: 0 | shares_owned_after: 113,457.00 | transaction_form_type: 4 | Footnotes: F1, F7

    Footnotes:

    • F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025.
    • F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
    • F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
    • F4: The option was fully vested and exercisable.
    • F5: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
    • F6: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
    • F7: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Search

News categories